Hoth Therapeutics (NASDAQ:HOTH) Trading 3.3% Higher

Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares were up 3.3% during trading on Thursday . The company traded as high as $1.25 and last traded at $1.23. Approximately 29,292 shares were traded during mid-day trading, a decline of 92% from the average daily volume of 371,291 shares. The stock had previously closed at $1.19.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a research report on Friday, April 5th.

Hoth Therapeutics Price Performance

The firm has a 50-day moving average price of $1.29 and a 200-day moving average price of $1.28.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.